US 12,391,945 B2
Coronavirus IRNA compositions and methods of use thereof
Akin Akinc, Needham, MA (US); James D. McIninch, Burlington, MA (US); Yesseinia Anglero-Rodriguez, Cambridge, MA (US); Mark K. Schlegel, Boston, MA (US); Christy M. Hebner, San Francisco, CA (US); and Florian A. Lempp, San Francisco, CA (US)
Assigned to Alnylam Pharmaceuticals, Inc., Cambridge, MA (US); and Vir Biotechnology, Inc., San Francisco, CA (US)
Filed by Alnylam Pharmaceuticals, Inc., Cambridge, MA (US); and Vir Biotechnology, Inc., San Francisco, CA (US)
Filed on Nov. 10, 2021, as Appl. No. 17/523,030.
Application 17/523,030 is a continuation of application No. 17/321,561, filed on May 17, 2021, granted, now 11,208,660.
Application 17/321,561 is a continuation of application No. PCT/US2021/024038, filed on Mar. 25, 2021.
Claims priority of provisional application 63/124,910, filed on Dec. 14, 2020.
Claims priority of provisional application 63/019,481, filed on May 4, 2020.
Claims priority of provisional application 63/001,580, filed on Mar. 30, 2020.
Claims priority of provisional application 62/994,907, filed on Mar. 26, 2020.
Prior Publication US 2022/0127615 A1, Apr. 28, 2022
Int. Cl. C12N 15/113 (2010.01)
CPC C12N 15/1131 (2013.01) [C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3515 (2013.01)] 22 Claims
 
1. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of a coronavirus genome in a cell, or a salt thereof,
wherein the dsRNA agent, or a salt thereof, comprises a sense strand and an antisense strand forming a double stranded region,
wherein the antisense strand comprises a nucleotide sequence differing by no more than three bases from any one of the antisense strand nucleotide sequences selected from the group consisting of
(a) 5′-CCGGGUUUGACAGUUUGAAAAGC-3′ of SEQ ID NO: 586;
(b) 5′-GAUUAAAGAUUGCUAUGUGAGAU-3′ of SEQ ID NO: 719; and
(c) 5′-UCGGGUUUGACAGUUUGAAAAGC-3′ of SEQ ID NO: 1852.